Human metapneumovirus (HMPV) is a major cause of pediatric respiratory illness, with evolving antigenic variants driving reinfections, variable disease severity, and challenges in diagnosis and vaccine development. Antigenic changes, mainly in the G glycoprotein, arise from high mutation rates, repeated infections, maternal antibodies, and rapid pediatric transmission, facilitating immune escape. Although the F protein is a conserved target for vaccines, genetic diversification complicates broadly protective vaccine design. Current vaccine strategies include subunit, virus-like particle (VLP), mRNA, live-attenuated, and multi-epitope platforms informed by genomic surveillance. In the absence of licensed vaccines or antivirals, nursing plays a pivotal role in early detection, infection prevention, supportive care, parental education, and reporting, helping reduce clinical severity, limit transmission, and strengthen public health preparedness.
No takes yet. Share an insight, caveat, or question.
S et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: